2451
|
Yang M, Yi X, Wang J, Zhou F. Electroanalytical and surface plasmon resonance sensors for detection of breast cancer and Alzheimer's disease biomarkers in cells and body fluids. Analyst 2014; 139:1814-25. [DOI: 10.1039/c3an02065g] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
2452
|
Lambertini M, Azim HA. Adjuvant hormonal therapy in young breast cancer patients. BREAST CANCER MANAGEMENT 2014. [DOI: 10.2217/bmt.13.67] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Matteo Lambertini
- Department of Medical Oncology, U.O. Oncologia Medica A, IRCCS AOU San Martino-IST, Genova, Italy
| | - Hatem A Azim
- BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
2453
|
Zhou J, Yan Y, Guo L, Ou H, Hai J, Zhang C, Wu Z, Tang L. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer. Saudi Med J 2014; 35:1324-30. [PMID: 25399208 PMCID: PMC4362150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/29/2022] Open
Abstract
OBJECTIVES To determine the outcome of patients with luminal A, luminal B, human epidermal growth factor receptor-2 (HER-2) positive, and triple negative molecular subtypes of inflammatory breast cancer (IBC) using a retrospective analysis. METHODS This study was conducted between February 2004 and February 2010 in 3 different hospitals in China. The clinical outcomes, pathological features, and treatment strategies were analyzed in 67 cases of IBC without distant metastases. A chi-square test and one-way ANOVA were used to assess outcomes between different subtypes. Overall survival (OS) was analyzed using the Kaplan-Meier method and multivariate analysis was conducted using the Cox regression model. RESULTS The 2-year OS rate was 55% for the entire cohort. Median OS time among patients with luminal A was 35 months, luminal B was 30 months, HER-2 positive was 24 months, and triple negative subtypes was 20 months, and were significantly different from each other (p=0.001). Using multivariate analysis, luminal A had 76% (p=0.037), luminal B had 54% (p=0.048), and HER-2 positive subtypes had 47% (p=0.032) decreased risk of death compared with the triple negative subtype. Furthermore, elevated Ki-67 labeling was associated with increased risk of death, while the surgical treatment significantly improved patient survival. CONCLUSION Breast cancer subtypes are associated with distinct outcomes in IBC patients. Patients that presented with triple negative IBC had poorer outcome than luminal A, luminal B, and HER-2 subtypes. These results indicate that IBC is a heterogeneous disease similar to the conventional breast cancer.
Collapse
Affiliation(s)
- Jingyu Zhou
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | - Yi Yan
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | - Lei Guo
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | | | - Jian Hai
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | - Chaojie Zhang
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | - Zhaoyun Wu
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.
| | - Lili Tang
- From the Departments of Breast Surgery (Zhou, Guo, Ou, Hai, Tang), and Urology (Yan), Xiangya Hospital, Central South University, and the Department of Breast and Thyroid Surgery (Zhang), Hunan Provincial People's Hospital, and the Department of Breast Surgery (Wu), Hunan Provincial Tumor Hospital, Changsha, Hunan, China.,Address correspondence and reprint request to: Prof. Lili Tang, Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. Tel. +86 (371) 89753516. Fax. +86 (134) 67508520. E-mail: /
| |
Collapse
|
2454
|
Kayahan M, İdiz UO, Gucin Z, Erözgen F, Memmi N, Müslümanoğlu M. Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer. THE JOURNAL OF BREAST HEALTH 2014; 10:201-208. [PMID: 28331672 DOI: 10.5152/tjbh.2014.1777] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 06/02/2014] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To detect the relationship between molecular subtypes of breast cancer with expressions of androgen receptor, cytokeratin 5/6 (CK5/6)and Ki-67. MATERIALS AND METHODS Expressions of androgen receptor, CK-5/6 and Ki-67 were determined by immunohistochemistry in paraffin-embedded sections obtained from 86 invasive breast cancer cases of stages I/IIa/IIb in 4 molecular subtypes. Patients treated for recurrent disease and locally advanced disease were excluded. RESULTS Forty one luminal A cases, ie. positive estrogen receptor(ER) and/or progesteron receptor (PR) with negative epidermal growth factor receptor (HER2), 14 luminal B, ie. positive ER and/or PR and positive HER2, 14 HER2-enriched (HER2+), ie. negative ER and PR with positive HER2, and 17 triple negative (negative ER and PR and HER2) invasive breast cancers were included. Mean follow-up was 17.46±11.70 mo. Androgen receptor-negativity and CK5/6-positivity were significantly more common in HER2+ and triple negative groups. Ki-67 and histological grade were higher in HER2+ group, significantly. Two deaths were triple negative (P=0.04). Androgen receptor-negativity, CK5/6 and Ki-67 status did not affect survival or systemic metastases, significantly. All groups had local recurrences. Local recurrence was significantly associated with androgen receptor-negativity in luminal A and high Ki-67 value in HER2+ groups. Systemic metastases were significantly more common in triple negative and HER2+ groups. CONCLUSION Molecular subtypes of breast cancer are prognostic and predictive. Androgen receptor is expressed more commonly in luminal subtypes with better prognosis and androgen receptor negativity is associated with development of local recurrence in luminal A cancers.
Collapse
Affiliation(s)
- Münire Kayahan
- Department of General Surgery, Bezmialem Vakif University Faculty of Medicine, İstanbul, Turkey
| | - Ufuk Oğuz İdiz
- Department of General Surgery, Bezmialem Vakif University Faculty of Medicine, İstanbul, Turkey
| | - Zuhal Gucin
- Department of Pathology, Bezmialem Vakif University Faculty of Medicine, İstanbul, Turkey
| | - Fazilet Erözgen
- Department of General Surgery, Haseki Training and Research Hospital, İstanbul, Turkey
| | - Naim Memmi
- Department of General Surgery, Bezmialem Vakif University Faculty of Medicine, İstanbul, Turkey
| | - Mahmut Müslümanoğlu
- Department of General Surgery, Bezmialem Vakif University Faculty of Medicine, İstanbul, Turkey
| |
Collapse
|
2455
|
Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D’Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D’Aiuto G. Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. Diabetol Metab Syndr 2014; 6:105. [PMID: 25285159 PMCID: PMC4183766 DOI: 10.1186/1758-5996-6-105] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Accepted: 09/22/2014] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can individually increase the risk of specific breast cancer subtype. METHODS Anthropometric and metabolic variables were correlated to breast cancer specific subgroups, retrospectively. Statistical significance was considered when p ≤ 0.05 and 95% CI. RESULTS Data analysis suggests that MS per se represents a modifiable risk factor for BC in postmenopausal [OR 6.28 (95% CI 2.79-14.11) p < 0.00001]. MS per se prevalence is higher among Luminal breast cancers in postmenopausal [OR 1.37 (95% CI 1.07-2.80) p = 0.03]. Body Mass Index (BMI) alone is associated to Luminal A subtype breast cancer risk [OR 1.12 (95% CI 0.96-2.196 p = 0.2]. Waist Circumference > 88 cm has been shown to be specifically and statistically significant associated to HER-2+ breast cancer subtypes in postmenopausal [OR 2.72 (95% CI 1.69- 10.72) p = 0.01], whilst in Luminal B it was only marginally statistical associated [OR 2.21 (95% CI 0.77-2.60) p = 0.1]. Insulin resistance showed statistical significant association to HER-2+ and Luminal B tumors [OR 2.11 (95% CI 1.66-6.69) p = 0.05] and [OR 2.33 (95% CI 1.2-4.2) p = 0.006], respectively. Hence, it has emerged that BMI is weakly associated to Luminal A breast cancers in this case series, whereas visceral obesity and insulin resistance are likely to be linked to more aggressive breast cancer subtypes. CONCLUSIONS New molecular biomarkers unveiling metabolic syndrome related breast carcinogenesis need to be detected to further stratify breast cancer risk by subtypes.
Collapse
Affiliation(s)
- Immacolata Capasso
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Emanuela Esposito
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Michelino de Laurentiis
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Nicola Maurea
- />Division of Cardiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Ernesta Cavalcanti
- />Division of Medicine Laboratory and Clinical Pathology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Gerardo Botti
- />Division of Pathology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Antonella Petrillo
- />Department of Radiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Maurizio Montella
- />Division of Epidemiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Massimiliano D’Aiuto
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Carmela Coppola
- />Division of Cardiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Anna Crispo
- />Division of Epidemiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Maria Grimaldi
- />Division of Epidemiology, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Giuseppe Frasci
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Alfredo Fucito
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Gennaro Ciliberto
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| | - Giuseppe D’Aiuto
- />Department of Breast Surgery and Cancer Prevention, “Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale – IRCCS - Italia”, Via Mariano Semmola, 80131 Naples, Italy
| |
Collapse
|
2456
|
Abstract
Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, K14+ cells led collective invasion in the major human breast cancer subtypes. Importantly, luminal cancer cells were observed to convert phenotypically to invasive leaders following induction of basal epithelial genes. Although only a minority of cells within luminal tumors expressed basal epithelial genes, knockdown of either K14 or p63 was sufficient to block collective invasion. Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression.
Collapse
Affiliation(s)
- Kevin J Cheung
- Departments of Cell Biology and Oncology, Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Edward Gabrielson
- Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Zena Werb
- Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Andrew J Ewald
- Departments of Cell Biology and Oncology, Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
| |
Collapse
|
2457
|
Mersich T, Faludi S, Ping O, Jóbaházi J, Szabó B, Dede K, Besznyák I, Bursics A. [Evolution of sentinel lymph node biopsy in breast cancer--axillary staging in the past 15 years at the Uzsoki Street Hospital]. Magy Seb 2013; 66:320-4. [PMID: 24333976 DOI: 10.1556/maseb.66.2013.6.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
INTRODUCTION Sentinel biopsy technique was performed in Europe in 1996.It was a great improvement in the surgical treatment of breast cancer, it decreased the number of patients suffering from early and late morbidity following axillary lymph node dissection (ALND). In our paper we demonstrate the evolution of sentinel biopsy technique (SLNB), as well as the changes in our policy on axillary treatment in line with the European trends. METHODS The authors of this article give an overview and analyse the relevant literature concerning sentinel lymph node biopsy and data of patients on whom sentinel lymph node biopsy was performed from 01/01/2001 to 31/12/2012. RESULTS Between 2001 and 2013 we performed 3756 breast operations, 2742 of those were done for malignant disease. Altogether we performed 744 sentinel lymph node biopsies in the Uzsoki teaching Hospital. The proportion of SLNB patients is increasing, it was 24.6% between 2001-2006 and 29.2% between 2007-2012, respectively. The indication of SLNB is widening, there might be justification of the technique even by multifocal or multilocular disease, in male patients, after former breats surgery or even in pregnant patients. CONCLUSION Histological examination of sentinel lymph node and its effect on complex treatment of breats cancer may place the role of surgical axillary staging in a brand new aspect in the near future perhaps.
Collapse
Affiliation(s)
- Tamás Mersich
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Sándor Faludi
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Orsolya Ping
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Jenő Jóbaházi
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Balázs Szabó
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Kristóf Dede
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - István Besznyák
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| | - Attila Bursics
- Uzsoki Utcai Kórház Sebészeti Osztály 1145 Budapest Uzsoki u. 29
| |
Collapse
|
2458
|
Cheung KJ, Gabrielson E, Werb Z, Ewald AJ. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013; 155:1639-51. [PMID: 24332913 DOI: 10.1016/j.cell.2013.11.029] [Citation(s) in RCA: 576] [Impact Index Per Article: 52.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Revised: 05/02/2013] [Accepted: 11/11/2013] [Indexed: 12/14/2022]
Abstract
Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, K14+ cells led collective invasion in the major human breast cancer subtypes. Importantly, luminal cancer cells were observed to convert phenotypically to invasive leaders following induction of basal epithelial genes. Although only a minority of cells within luminal tumors expressed basal epithelial genes, knockdown of either K14 or p63 was sufficient to block collective invasion. Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression.
Collapse
Affiliation(s)
- Kevin J Cheung
- Departments of Cell Biology and Oncology, Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Edward Gabrielson
- Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Zena Werb
- Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA
| | - Andrew J Ewald
- Departments of Cell Biology and Oncology, Center for Cell Dynamics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
| |
Collapse
|
2459
|
Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 2013; 232:219-29. [DOI: 10.1002/path.4269] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Revised: 09/15/2013] [Accepted: 09/16/2013] [Indexed: 12/12/2022]
Affiliation(s)
- Filippo Montemurro
- Unit of Investigative Clinical Oncology (INCO) and Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia; Institute of Candiolo (IRCCs); Str Provinciale 142 10060 Candiolo Italy
| | - Maurizio Scaltriti
- Human Oncology & Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center; 1275 York Avenue, Box 20 New York NY 10065 USA
| |
Collapse
|
2460
|
Gluz O, Hofmann D, Würstlein R, Liedtke C, Nitz U, Harbeck N. Genomic profiling in luminal breast cancer. Breast Care (Basel) 2013; 8:414-22. [PMID: 24550749 PMCID: PMC3919430 DOI: 10.1159/000357535] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.
Collapse
Affiliation(s)
- Oleg Gluz
- Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany
| | - Daniel Hofmann
- Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany
| | | | - Cornelia Liedtke
- Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Germany
| | - Ulrike Nitz
- Evangelisches Krankenhaus, Bethesda Mönchengladbach GmbH, Mönchengladbach, Germany
| | - Nadia Harbeck
- Brustzentrum, Ludwig-Maximilians-Universität München, Germany
| |
Collapse
|
2461
|
Souchon R, Sautter-Bihl ML, Sedlmayer F, Wenz F, Budach W, Sauer R. Radiation oncologists' view on the zurich consensus. Breast Care (Basel) 2013; 8:448-52. [PMID: 24550754 PMCID: PMC3919487 DOI: 10.1159/000357417] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Rainer Souchon
- Klinik für Radioonkologie und Strahlenklinik, Klinikum Karlsruhe, Germany
| | | | - Felix Sedlmayer
- Universitätsklinik für Radiotherapie und Radio-Onkologie, Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, LKH, Salzburg, Austria
| | - Frederik Wenz
- Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Germany
| | - Wilfried Budach
- Klinik für Strahlentherapie und Radiologische Onkologie, Universitätsklinikum Düsseldorf, Germany
| | - Rolf Sauer
- Strahlenklinik, Universitätsklinikum Erlangen, Germany
| |
Collapse
|
2462
|
Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Eur J Cancer 2013; 50:517-24. [PMID: 24275214 DOI: 10.1016/j.ejca.2013.10.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2013] [Revised: 10/27/2013] [Accepted: 10/30/2013] [Indexed: 01/09/2023]
Abstract
BACKGROUND Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. In addition, impact on survival has been demonstrated. The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event. MATERIALS AND METHODS The cohort includes 1504 patients, diagnosed with a primary DCIS between 1986 and 2004. Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. ER and PR were identified by immunohistochemistry (IHC) and HER2 by silver-enhanced in situ hybridisation (SISH) as well as IHC. RESULTS ER (n=112), PR (n=113) and HER2 (n=114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively. The receptor conversion was both from negative to positive and from positive to negative with no general pattern being seen in spite of sub-dividing into in situ relapse and invasive relapse. However, primary DCIS was HER2 positive in 40.3% whereas in situ and invasive relapses were HER2 positive in 42.9% and 34.5% respectively. CONCLUSIONS Receptor conversion for ER, PR and HER2 status occurred between primary DCIS and corresponding local relapse in 10-30%. This study could not confirm that HER2 overexpression in primary DCIS had any impact on tumour progression to invasive cancer which has been proposed.
Collapse
Affiliation(s)
- E Karlsson
- Department of Oncology-Pathology, Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden; Department of Oncology, Central Hospital Karlstad, Karlstad, Sweden.
| | - K Sandelin
- Department of Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - J Appelgren
- Department of Economics and Statistics, Karlstad University, Karlstad, Sweden
| | - W Zhou
- Department of Surgery, Uppsala University, Uppsala, Sweden
| | - K Jirström
- Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - J Bergh
- Department of Oncology-Pathology, Radiumhemmet, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden
| | - F Wärnberg
- Department of Surgery, Uppsala University Hospital, Uppsala, Sweden
| |
Collapse
|
2463
|
Zhou W, Jirström K, Amini RM, Fjällskog ML, Sollie T, Lindman H, Sørlie T, Blomqvist C, Wärnberg F. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 2013; 13:512. [PMID: 24171825 PMCID: PMC4228470 DOI: 10.1186/1471-2407-13-512] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Accepted: 10/23/2013] [Indexed: 12/19/2022] Open
Abstract
Background Different molecular subtypes of breast cancer have been identified based on gene expression profiling. Treatment suggestions based on an approximation of these subtypes by immunohistochemical criteria have been published by the St Gallen international expert consensus panel. Ductal carcinoma in situ (DCIS) can be classified into the same molecular subtypes. Our aim was to study the relation between these newly defined subtypes and prognosis in DCIS. Methods TMA including 458 women from a population-based cohort with DCIS diagnosed 1986–2004 was used. Stainings for ER, PR, HER2 and Ki67 were used to classify the surrogate molecular subtypes according to the St Gallen criteria from 2011. The associations with prognosis were examined using Kaplan-Meier analyses and Cox proportional hazards regression models. Results Surrogate molecular subtyping could be done in 381 cases. Mean follow up was 164 months. Of the classified DCIS 186 were Luminal A (48.8%), 33 Luminal B/HER2- (8.7%), 74 Luminal B/HER2+ (17.4%), 61 HER2+/ER- (16.0%) and 27 Triple Negative (7.1%). One hundred and two women had a local recurrence of which 58 were invasive. Twenty-two women had generalised disease, 8 without a prior local recurrence. We could not find a prognostic significance of the molecular subtypes other than a higher risk of developing breast cancer after more than 10 years of follow-up among women with a Triple Negative DCIS (OR 3.2; 95% CI 1.1-9.8). Conclusions The results from this large population-based cohort, with long-term follow up failed to demonstrate a prognostic value for the surrogate molecular subtyping of DCIS using the St Gallen criteria up to ten years after diagnosis. More than ten years after diagnosis Triple Negative DCIS had an elevated risk of recurrence.
Collapse
Affiliation(s)
- Wenjing Zhou
- Department of Surgical Science, Uppsala University, Uppsala SE-75105, Sweden.
| | | | | | | | | | | | | | | | | |
Collapse
|
2464
|
|
2465
|
Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, Suzuki K, Sakurai O, Nakamura S. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 2013; 22:406-12. [PMID: 24081457 DOI: 10.1007/s12282-013-0495-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 09/02/2013] [Indexed: 12/22/2022]
Abstract
BACKGROUND OncotypeDX(®) (ODX) is a well-validated assay for breast cancer treatment planning. We explored whether the conventional pathological factors could pick up high risk patients without the help of the ODX. METHODS The ODX was performed on 139 hormone receptor-positive invasive breast cancers in a single Japanese institution. The recurrence risk was compared between the ODX and the St. Gallen Consensuses. The correlations were analyzed between the Recurrence Score (RS) measured by ODX and the pathological factors. In addition, we performed a follow-up survey and examined the association of the RS with the confirmed recurrence or death. RESULTS The ODX classified 68 (49 %) as low RS, 52 (37 %) as intermediate RS, and 19 (14 %) as high RS cases. Correlations were noted between RS and progesterone receptor (PR) (r = -0.53), Ki-67 (r = 0.42), and nuclear grade (NG) (r = 0.41). None had a high RS with PR(3+) or NG1. Only one high RS patient had a Ki-67 (<20 %). The combinations of high RS with PR(0)/Ki-67 (≥20 %) and PR(1+)/Ki-67 (≥20 %) were 70 and 58 %, respectively. The combinations with high RS and PR(0)/NG3, PR(0)/NG2, and PR(1+)/NG3 were 83, 75, and 75 %, respectively. The median follow-up was 39.1 months (range 24.0-67.8). There were one low RS (1 %), four intermediate RS (8 %), and three high RS patients (16 %) who developed local or distant recurrence. CONCLUSION Hormone receptor-positive invasive breast cancers are stratified with the combinations of PR/Ki-67 or PR/NG. Some of the high recurrence risk cases might be identified without the ODX.
Collapse
Affiliation(s)
- Toshinao Onoda
- Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan,
| | | | | | | | | | | | | | | | | |
Collapse
|
2466
|
Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi7-23. [PMID: 23970019 DOI: 10.1093/annonc/mdt284] [Citation(s) in RCA: 329] [Impact Index Per Article: 29.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | | | | | | | | | | | | | | |
Collapse
|